fda-overview-protecting-consumers-promoting-public->fda-retail-food-protection-program-foodborne-illne Content Directory

FDA Resources and Meetings
FDA OVERVIEW: Protecting Consumers - Promoting Public Health
FDA OVERVIEW: Protecting Consumers - Promoting Public Health
FDA Panel Digital Pathology Oct 22/23
FDA Part 11 Public Meeting Washington, DC June 11, 2004
Dhiren N. Shah, Ph.D. Director, DRA-CMC Aventis Pharmaceuticals
FDA, PDUFA AND MEDICAL INNOVATION Spring 2012
FDA Pediatric Oncology Subcommittee Meeting
FDA Peptide Ban What It Means for Peptide Therapy
FDA Perspective: FDA Evaluation of Point of Care Blood Glucose Meters
FDA Perspective: FDA Evaluation of Point of Care Blood Glucose Meters
FDA Perspective: FDA Evaluation of Point of Care Blood Glucose Meters
FDA Perspective on Cardiovascular Device Development
FDA Perspective on Cardiovascular Device Development
FDA Perspective on Direct Acting Antiviral Trials
FDA Perspective on Global Evaluation of Facial Acne
FDA Perspective on Nanomaterial-Containing Products
FDA Perspective on Nanomaterial-Containing Products
Therac-25 Case
FDA Perspective on Review of Innovative Systems for Drug Delivery
FDA Perspective on the Development of Cellular Therapies for Repair and Regeneration of Joint Surfaces - Preclinical Pe
FDA Perspective on the PASSPORT Study
FDA perspective on “Where are we? Where can we go?” 12 th Annual FDA & the Changing Paradigm for Blood Regulation
FDA Perspective
FDA Perspectives (I)
FDA Perspectives (I)
FDA Perspectives on Clinical Trial Development of Gene Therapy
FDA Perspectives on Clinical Trial Development of Gene Therapy
FDA Perspectives on Clinical Trial Development of Gene Therapy
FDA Perspectives on Erythropoiesis-Stimulating Agents (ESAs) for Anemia of Chronic Renal Failure: Hemoglobin Target and
FDA Pharmacogenetic Labels A Clinical Perspective
FDA/ PhUSE CSS - Working Group 5 - Analysis Standards Script Examples
FDA/ PhUSE CSS - Working Group 5 - Analysis Standards Script Examples
FDA/PhUSE WG 5
Selection of antibiotics for acute otitis media: Application of pharmakokinetic and pharmacodynamic principles
FDA Pregnancy Categories – Understanding Drug Safety in Pregnancy and Nursing
FDA Pregnancy Categories – Understanding Drug Safety in Pregnancy and Nursing
FDA Prehistory
FDA Prehistory
FDA Preliminary Concept Paper Sterile Drug Products Produced by Aseptic Processing
Prescription Drug Importation Public Meeting April 14, 2004
FDA Presentation
FDA Presentation NDA 21-661 RSR13 ( efaproxiral sodium )
FDA Presentation ODAC Meeting July 24 2007
FDA Presentation to BPAC: NMRC RESUS Protocol Using HBOC-201
FDA Presentation to the Oncologic Drugs Advisory Committee
FDA Presentation to the Oncologic Drugs Advisory Committee Tositumomab Therapeutic Regimen Corixa Corporation BLA 1250
FDA Preventive Control Regulation
FDA Process Cleaning Method SAP Validation
FDA Process Registration Forms 2541 and 2541a Module 2210
FDA Processes for Assuring Safety and Efficacy for Ophthalmic Drugs
FDA PROMOTIONAL RULES
FDA PROPOSED DISCLOSURE RULE
FDA Public Hearing: Medical Device User Fee Program September 14, 2010
Steve Brotman, MD, JD Senior Vice President, Payment and Health Care Delivery Policy, AdvaMed
FDA Public Hearing on Reporting of Adverse Events to Institutional Review Boards (21 March 2005)
What is CIOMS?
FDA Public Meeting: Device Improvements and Reporting
FDA Public Meeting June 10, 2010
FDA Public Meeting on Electronic Records and Signatures June 11, 2004
FDA Public Meeting on New Dietary Ingredients
FDA Public Meeting
FDA Public Meeting Preparation for the ICH Meetings in Tokyo, Japan, Including Progress on
FDA Public Meeting The Future of the International Conference on Harmonization of Technical
FDA Recalls
FDA Recalls – DET-DO Organization
FDA Recognition of Clinical Spectrum in the Dementias
FDA recommendation: people should consume less than 65 grams of fat per day.
FDA recommendation: people should consume less than 65 grams of fat per day.
FDA Recommended Study Design for CABG Anastomosis Devices
MICROBIAL FOOD SAFETY A FOOD SYSTEMS APPROACH
FDA Registered Manufacturers
FDA-Registered vs FDA-Approved vs FDA-Cleared
fda registration
fda registration
FDA Registration and FDA Approval Process Online - FDAhelp
FDA Registration Guide for Food and Drug Companies
FDA Regulated Research: Current Challenges with Investigational Devices Lynn Henley, M.S., M.B.
FDA Regulation of Bacterial Vaccines
FDA Regulation of Cell Therapy
FDA Regulation of Cell Therapy
FDA Regulation of Cellular, Tissue, and Gene Therapies
FDA Regulation of Combination Products
FDA Regulation of Diagnostic Tests
FDA Regulation of Diagnostic Tests
FDA Regulation of Drug Quality: New Challenges
FDA Regulation of Drug Quality: New Challenges
Machine Learning Regulated by the FDA
FDA Regulation of In Vitro Diagnostic Tests
FDA Regulation of In Vitro Diagnostic Tests
FDA Regulation of In Vitro Diagnostic Tests
FDA Regulation of In Vitro Diagnostic Tests
FDA Regulation of Lead in Food
FDA Regulation of Mobile Apps
FDA Regulation of Obesity Drugs: 1938 - 1999
FDA Regulation of Pharmaceutical Marketing
FDA Regulation of Pharmaceuticals and Devices
FDA Regulation of Pharmaceuticals and Devices
FDA Regulation of Pharmaceuticals and Devices
FDA Regulation of Pharmaceuticals and Devices
FDA Regulation of Product Claims
FDA Regulation of the Dissemination of Medical Device Information Daniel A. Kracov Medical Device Congress Marc
FDA Regulation of Tobacco: What does it mean? When does it start? And what’s next?
2019 Policy Priorities Laura MacCleery Policy Director
FDA Regulations and Compliance: Ensuring Safety in the Industry
FDA Regulations Checklist for Eliquid Manufacturers and Vape Shop Online
FDA Regulations Governing GCP, GLP and GMP
FDA Regulations Pertaining to Good Clinical Practice and Clinical Trials
FDA Regulatory & Compliance Symposium Cambridge, August 26, 2005
FDA Regulatory & Compliance Symposium Special Pre-Conference Workshop August 24, 2005
FDA Regulatory Considerations for the Biomedical Start-Up
FDA Regulatory Consulting Service for Medical Devices
FDA Regulatory Exclusivity and Patent Protection for Drugs
FDA Regulatory Framework for Devices Applied to HIT
FDA Regulatory Framework for Devices Applied to HIT
FDA Regulatory Perspective: Data Integrity
FDA Regulatory Perspectives on Immunogenicity Risk Assessment from Phase 1 IND to BLA and Beyond
FDA Regulatory, Policy, and Enforcement Development Key Trends in 2015
FDA regulatory requirements for medical devices
FDA Regulatory Requirements & The Food Safety Modernization Act
FDA Regulatory Requirements to Market Medical Devices in the United States (U.S.)
FDA Regulatory Training Courses | FDA Webinars | FDA Training
FDA Releases Draft Guidance on Enforcement Discretion for Certain NAC Products
FDA Reprimands Merck for the Release:
FDA Reproductive Health Drug Advisory Committee Meeting August 29, 2006 Gaithersburg, Maryland
FDA Research: Clearance Requirements and Implications
FDA Resources and Meetings

Browse slideshows:
a
b
c
d
e
f
g
h
i
j
k
l
m
n
o
p
q
r
s
t
u
v
w
x
y
z
0
1
2
3
4
5
6
7
8
9